DISUFENTON

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H15NO7S2
Molecular Weight	337.369
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0
Stereo Comments	MM2 minimum energy of Z and E are 288.5886 and 451.3651 kcal/mol respectively

SHOW SMILES / InChI

SMILES

CC(C)(C)[N+](\[O-])=C\C1=C(C=C(C=C1)S(O)(=O)=O)S(O)(=O)=O

InChI

InChIKey=OVTCHWSLKGENKP-GHXNOFRVSA-N

InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)/b12-7-

HIDE SMILES / InChI

Molecular Formula	C11H15NO7S2
Molecular Weight	337.369
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description

AstraZeneca developed disufenton (NXY-059), a free radical trapping agent, for the treatment of ischaemic stroke and other brain injuries. Nevertheless, large clinical trial (3306 versus 1722 patients) was neutral, providing no evidence for the efficacy of disufenton sodium in patients with stroke. One study using rat cortical brain slices concluded that NXY-059 improved neuronal survival. However, another study in mouse neuroblastoma cells reported no effect. Another study reported that NXY-059 restored endothelial blood-brain. Histological analyses revealed several therapeutic advantages associated with disufenton sodium treatment following acute acoustic trauma, including reductions in inner and outer hair cell loss; reductions in acute acoustic trauma-induced loss of calretinin-positive afferent nerve fibers in the spiral lamina; and reductions in fibrocyte loss within the spiral ligament. However, AstraZeneca terminated the development program.